

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2941808

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MARK KLINGER	03/28/2014
MALEK FAHAM	03/28/2014
RECEIVING PARTY DATA	
Name:	SEQUENTA, INC.
Street Address:	400 East Jamie Court
Internal Address:	Suite 301
City:	South San Francisco
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14242520
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(650) 892-9848
Email:	steve.macevicz@sequentainc.com
Correspondent Name:	STEPHEN C. MACEVICZ
Address Line 1:	400 EAST JAMIE COURT
Address Line 2:	SUITE 301
Address Line 4:	SOUTH SAN FRANCISCO, CALIFORNIA 94080
ATTORNEY DOCKET NUMBER:	852US00 (37623-743.201)
NAME OF SUBMITTER:	STEPHEN C. MACEVICZ
SIGNATURE:	/Stephen C. Macevicz/
DATE SIGNED:	07/16/2014
Total Attachments: 2	
source=852US00-Assignment#page1.tif	
source=852US00-Assignment#page2.tif	

ASSIGNMENT

For good and valuable consideration paid to me (for single inventor) us (for joint inventors), receipt of which is hereby acknowledged, I (we each):

Mark Klinger

Malek Faham

do hereby sell, assign, and set over unto

Sequentia, Inc.

(formerly named "MLC Dx Incorporated"), a Delaware corporation, having a principal office at 400 East Jamie Court, Suite 301, South San Francisco, California 94080 (hereinafter "Assignee"), its successors, legal representatives and assigns, my (each of our) entire right, title, and interest (1) in and to any and all of my (our) inventions and discoveries entitled:

Determining Antigen-Specific T Cells

as described and/or claimed in my (our) patent application(s), identified as follows, a copy of which I (we) acknowledge receipt of and/or having received:*

Ser. No.	Filed
14/242520	01-April-2014

(2) in and to the right to file patent applications in the name of Assignee, its designee, in my name (any or all of our names), or in any other name or names, on the aforesaid inventions and discoveries in any or all countries of the world, together with all rights of priority in the aforesaid countries deriving from the above-identified patent application under the International Convention for the Protection of Industrial Property, or under any other international arrangement applicable to the above-identified patent application; (3) in and to any and all applications for Letters Patent, and any and all Letters Patent that issue on any of the aforesaid applications, and (4) in and to any and all conversion applications, divisions, continuations, and continuations-in-part of any and all of said applications, and any and all reissues, renewals and extensions of any of said Letters Patent, such that the same right, title and interest to be held and enjoyed by Assignee, its successors, assigns or other legal representatives, to the full ends of the terms for which all Letters Patent therefor may be granted, shall be as full and complete as that that would have been held and enjoyed by me (us) if this assignment and sale had not been made. The terms and covenants of this Assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said inventors, their respective heirs, legal representatives and assigns.

I (we) further hereby covenant and agree, for the same consideration, whenever counsel of Assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with said invention, or said application for Letters Patent, including interference proceedings, is lawful and desirable, or that any division, continuation, or continuation-in-part of any application for Letters Patent, or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, to sign all papers and documents, take all lawful oaths, and

* I (we) hereby authorize Assignee to insert in this instrument the serial number and filing date of said application when officially notified thereof.


do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said invention, without charge to said Assignee, its successors, legal representatives and assigns, but at the cost and expense of said Assignee, its successors, legal representatives and assigns.

Special Power of Attorney

To the extent allowable by law, I (we) hereby appoint Assignor, acting through any of its officers, as my (our) attorney-in-fact to act in my (our) name and capacity to do any and all of the following: To execute any document necessary or desirable for the purpose of securing, prosecuting, maintaining, enforcing, and/or defending the patents and patent applications referred to above, including any and all foreign counterparts, divisions, continuations, continuations-in-part, extensions, substitutes, reissues, or renewals thereof; and to represent me (us) and to transact all business related to securing, prosecuting, maintaining, enforcing, and/or defending the patents and patent applications referred to above, in or before any national or international patent office, agency, bureau, or tribunal.

This Power of Attorney shall be effective upon execution and shall remain in full force and effect until the expiration of the last-to-expire patent or the last-to-expire patent based on any application referred to above, including any foreign counterparts, divisions, continuations, continuations-in-part, extensions, substitutes, reissues, or renewals thereof.

Understood and Agreed:



Malek Faham

28 March 14

Date




Witness

3/28/2014

Date

Stephen C. Macevicz


Name (printed)



Mark Klinger

28 March 14

Date



Witness

3/28/2014

Date

Stephen C. Macevicz

Name (printed)